CDK4 and renal carcinoma: On the one hand, we did not combine CDK4/6 inhibitors or other drugs to further explore their therapeutic effects in animal models of renal cancer; we used the A498 and 786-O cell lines in this study, and we may have to validate the findings in more renal cancer cell lines in the future.